Effect of amphotericin B and fluconazole on platelet membrane glycoproteins.
BACKGROUND
Fever, chills, and reduced platelet recovery may result when platelets are transfused simultaneously with amphotericin B. Amphotericin B reportedly increases the pitting of membranes in stored platelets.


METHODS
The effects of amphotericin B and another antifungal agent, fluconazole, on platelet membrane glycoproteins (GP) were examined by the incubation of split aliquots of fresh and stored platelet concentrates (PCs) with these drugs for 3 days in storage bags. To determine the effect of storage, PCs were stored for 5 days, and aliquots removed on Days 1 through 5 were placed in platelet storage bags with 4 micrograms per mL of amphotericin B for 2 to 6 hours. Membrane glycoprotein expression was assessed by flow cytometry with fluorescein isothiocyanate-labeled monoclonal antibodies (MoAbs) directed against the following antigens: GPIb (CD42b), CD63 (an activation protein), P-selectin (CD62), and GPIIb/IIIa (CD41a).


RESULTS
Amphotericin B produced a concentration-dependent decrease in the surface binding of CD42b MoAb with no consistent changes in the binding of CD41a, CD63, or CD62 MoAbs after a 3-day exposure. Stored but not fresh PCs showed decreased binding of MoAb CD42b after a 6-hour exposure to amphotericin B (4 micrograms/mL). Fluconazole produced no changes. When the binding of MoAb CD42b to permeabilized platelets was used to measure total platelet content, amphotericin B (4 micrograms/mL) decreased MoAb CD42b binding to a similar degree in fresh and stored platelets. Inhibition of aggregation to ADP and collagen and ADP and epinephrine was seen in stored but not fresh PCs.


CONCLUSIONS
Therapeutic levels of amphotericin B resulted in partial loss of total platelet GPIb in fresh and stored PCs, but decreased surface expression of platelet membrane GPIb only in stored platelets. This difference between fresh and stored platelets may be related to the limited reservoir of GPIb available for redistribution to the membrane in the previously stored PCs and may account for the decreased recovery of transfused platelets observed in some patients receiving amphotericin B.
Sloand
E M
EM
National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Kumar
P
P
Yu
M
M
Klein
H G
HG
D000666:Amphotericin B / Q000494:pharmacology*; D001666:Binding Sites, Antibody; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology; D001793:Blood Preservation; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D007962:Leukocytes / Q000502:physiology; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects*; D012709:Serum Albumin / Q000494:pharmacology
D010980:Platelet Membrane Glycoproteins; D012709:Serum Albumin; D000666:Amphotericin B; D015725:Fluconazole